

BACE1 inhibitors with antioxidant activity

Design, synthesis and biological activity evaluation of BACE1 inhibitors with antioxidant activity

He-Min Li, Shao-Peng Yu, Tian-Yuan Fan, Yue Zhong, Ting Gu, Wen-Yu Wu, Nian-Guang Li*

Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China

*Corresponding authors. Tel/fax: +86 25 85811916

E-mail addresses: linianguang@njutcm.edu.cn

ABSTRACT

The proteolytic enzyme β -secretase (BACE1) plays a central role in the synthesis of the pathogenic β -amyloid peptides ($A\beta$) in Alzheimer's disease (AD). In this study, BACE1 inhibitors (**D1–D18**) with free radical scavenging activities were synthesized by molecular hybridization. The biological activity evaluation showed that **D1** had obvious inhibitory activity of BACE1, and strong antioxidant activity in DPPH and ABTS⁺ assay, which could be used as a lead compound for further study.

Keywords: Alzheimer's disease, BACE1, Antioxidant activity, Molecular hybridization, Molecular docking

1. INTRODUCTION

For the older people, the Alzheimer's Disease (AD) is the most common reason to cause dementia, it consisted a progressive and chronic neurodegenerative disorder [1]. The clinical symptoms of AD are memory loss and difficulties with language, thinking or problem-solving. In fact, the therapies for AD only succeeded in slowing the cognitive decline. The pathological features of AD include two kinds of lesions in the patient brain, the first kind is the extracellular accumulation of amyloid plaques which is composed of the β -amyloid ($A\beta$) peptide, and the second kind is the intracellular neurofibrillary tangles (NFT) which is produced from the aggregation of hyperphosphorylated microtubule-associated tau protein [2].

The $A\beta$ is formed in a sequential proteolytic process, which is consisted of the cleavage of the amyloid precursor protein (APP). The β secretase, also called as Beta-site Amyloid precursor protein (APP) Cleaving Enzyme 1 (BACE1), is an enzyme that initiates $A\beta$ formation by hydrolysis of the APP extracellular domain, thus generates the membrane bound C-terminal fragment C99 and the N-terminal $A\beta$ fragment [3]. Subsequently, intramembrane processing of the former fragment C99 by γ -secretase affords $A\beta$ [4]. Most $A\beta$ peptides end at residue 40 but about 5–10% terminates at residue 42, which is a major actor in the pathogenesis of AD. So both of

BACE1 inhibitors with antioxidant activity

β secretase and γ secretase are required for the formation of A β , and the modulation or inhibition of these two enzymes has been regarded as an important therapeutic method to reduce the cerebral A β concentrations in AD patients. The studies with knockout mice in the absence of BACE1 showed that both wild type and mutant forms of APP failed to produce A β . Interestingly, these mice were in good health and did not show any side effects of BACE1 deficiency, thus evinced the key role of BACE1 in APP processing [5] and further confirmed that BACE1 was very important as a target to therapeutically intervene AD.

The research on BACE1 inhibitors was initiated from the substrate-based design of transition-state compounds, the cleavable amide bond of APP was replaced by a stable mimetic of the putative transition-state structure [6]. Thus some peptidomimetic inhibitors have been designed, such as hydroxyethylene and statine-based agents, these compounds exhibited potent in vitro subnanomolar activities. However, some peptidic inhibitors suffered from poor pharmacological properties, because they had unfavorable physicochemical characteristics and poor brain penetration [7-9]. So in the past decades, the study to develop potent non-peptidic small-molecule BACE1 inhibitors has become the focus of many academic and pharmaceutical researchers [10], and some candidates have been put into clinical studies.

The first generation of orally active BACE1 inhibitor, BI 1181181 failed in Phase I trials because of low oral bioavailability and low blood-brain barrier penetration. Then the second-generation BACE1 inhibitors, LY2811376 (Phase I), LY2886721 (Phase II) and RG7129 (Phase I) also failed in clinical trials because they had liver toxicity. Fortunately, the third-generation BACE1 inhibitors including AZD3293 (Phase III), E2609 (Phase III), JNJ-54861911 (Phase II/III) and CNP520 (Phase II/III) have shown encouraging clinical data and satisfactory pharmacokinetics in ongoing studies. Although MK-8931 reduces CNS A β in animal models and in AD patients, however, Merck has stopped the clinical trial in mild-to-moderate AD patients because it showed minor efficacy [11].

In recent years, more attention has been paid to oxidative stress because of its role in AD [12]. Several studies have indicated that the antioxidant defense system in some elderly people lost its ability to neutralize the oxidative substance. In the early AD stage, the oxidative stress could initiate the Ab aggregation and tau protein hyperphosphorylation [13]. Many evidences have proved that the antioxidants could attenuate the AD syndrome, and prevent the disease progression [13]. Thus, drugs with specifically antioxidant activity might be useful for either the prevention or the treatment of AD.

So in this manuscript, we designed and synthesized a series of BACE1 inhibitors with antioxidant activities. Considering that the BACE1 inhibitors bearing 2-aminopyridine had a superior brain penetration [14], and the X-ray structure crystal studies showed that the 2-aminopyridine interacts with the catalytic acids Asp32 and Asp228 in BACE1 enzyme via a hydrogen-bonding network [15]. Furthermore, some natural antioxidants including hydroxycinnamic acid derivatives, ferulic acid [16], sinapic acid [17] and caffeic acid [18] have been shown to scavenge effectively

BACE1 inhibitors with antioxidant activity

radicals and to repair the oxidizing OH adducts of DNA via electron transfer reactions. So in this study, BACE1 inhibitors (**D1–D18**) (Fig. 1) bearing 2-aminopyridine with natural antioxidants were designed and synthesized by molecular hybridization.





Fig. (1). The design of BACE1 inhibitors (**D1–D18**) bearing 2-aminopyridine with natural antioxidants.

2. CHEMISTRY

The compounds were prepared according to Scheme 1. Treatment of amino-pyridine **S1** with o-phthalic anhydride produced imide **S2**, which was brominated by NBS to afford benzyl bromide **S3** and **S4**. In order to improve the yield of compound **S3**, we subsequently optimized this reaction condition by changing the ratio of NBS and AIBN, and we found that the best reaction condition for the synthesis of the target compound **S3** as the main product was that the ratio of NBS and AIBN should be 1.1 equiv. and 0.1 equiv., which afforded **S3** and **S4** in 46.7% and 21.3% respectively. Then the reaction of **S3** with phthalimide potassium salt afforded **S5** which could produce amine hydrochloride **S6** after hydrolysis with hydrochloric acid. At last, the target compounds **D1–D18** were obtained by reaction of **S6** and substituted acids using EDCI, HOBT and DIPEA as condensation agents.



Scheme 1. Reagents and conditions: a) o-Phthalic anhydride (1.0 equiv.), CH_3COOH , reflux, 5 h, 95.2%; b) NBS (1.1 equiv.), AIBN (0.1 equiv.), benzene, 85 °C, 5 h, **S3** (46.7%), **S4** (21.3%); c) Phthalimide potassium salt (1 equiv.), DMF, 160 °C for 4 h, r.t. overnight, 90.3%; d) HCl, reflux, 20 h, 93.7%; e) Acid, EDCI (1.2 equiv.), HOBT (1.2 equiv.), DIPEA (4.0 equiv.), r.t. overnight, 78.8%–89.6%.















3. RESULTS AND DISCUSSION

3.1. Effects of Compounds on BACE1 Inhibiting Activity





Table 1. The inhibitory activity on BACE 1 and antioxidant activities of compounds

Compd.	R	Inhibition rate (%) (at 2 μM)	Activity (IC_{50} , μM)	Compd.	DPPH assay IC_{50} (μM)	ABTS assay IC_{50} (μM)
--------	---	---	---	--------	---	---

BACE1 inhibitors with antioxidant activity

EGCG		56.41 ± 0.47	1.18 ± 0.41	Trolox	21.53	26.83
D1		53.22 ± 1.19	1.80 ± 0.22	D-1	67.85	27.14
D2		43.52 ± 3.59	N.D. ^a	D-2	N.D. ^a	N.D. ^a
D3		47.53 ± 3.34	N.D.	D-3	18.67	24.83
D4		51.61 ± 2.50	2.07 ± 0.51	D-4	N.D.	27.79
D5		52.61 ± 1.71	1.96 ± 0.60	D-5	53.64	23.76
D6		47.29 ± 0.50	N.D.	D-6	N.D.	45.82
D7		40.18 ± 3.22	N.D.	D-7	N.D.	40.11
D8		9.03 ± 2.24	N.D.	D-8	N.D.	83.45.
D9		6.54 ± 1.76	N.D.	D-9	N.D.	N.D.
D10		4.07 ± 2.34	N.D.	D-10	N.D.	N.D.
D11		3.12 ± 3.04	N.D.	D-11	N.D.	72.91
D12		4.79 ± 0.51	N.D.	D-12	35.21	35.58
D13		4.98 ± 3.06	N.D.	D-13	N.D.	40.63
D14		0	N.D.	D-14	N.D.	N.D.

BACE1 inhibitors with antioxidant activity

D15		0	N.D.	D-15	N.D.	N.D.
D16		0	N.D.	D-16	N.D.	N.D.
D17		0	N.D.	D-17	N.D.	N.D.
D18		1.80 ± 2.29	N.D.	D-18	N.D.	27.56

^a N.D.: Not Determined.

Epigallocatechin gallate (EGCG) has been proved to be a BACE1 inhibitor with its IC₅₀ value was 1.6 μmol·L⁻¹ [19]. So in this research, EGCG was used as positive control for the evaluation of BACE1 inhibiting activity, and the results were shown in Table 1. From the results, we could see that **D1–D7** had potent inhibitory activity against BACE1, compared to EGCG with its IC₅₀ was 1.18 μM. For compounds **D2**, **D3**, **D6** and **D7** where there were benzene ring or hydroxyl substituted benzene ring in the R substituents, the inhibition rates were less than 50% in the concentration of 2 μmol·L⁻¹. Interestingly, in compounds **D1**, **D4** and **D5** where the methoxy group was introduced, the inhibitory activities against BACE1 were improved with their inhibition rates were all above 50%, and the IC₅₀s for these three compounds were 1.80 μM, 2.07 μM and 1.96 μM respectively, this information indicated that introduction of methoxy group was very important for the inhibitory activities against BACE1. When the vinyl group was removed, the obtained compounds **D8–D13** and **D18** lost their inhibitory activities dramatically with their inhibition rates were all below 10%, this information confirmed that cinnamyl group in the side chain were very important to inhibit BACE1. Unfortunately, compounds **D14–D17** with no phenolic hydroxyl group was substituted in the benzene ring were inactive in this research, these results indicated that the phenolic hydroxyl group in the side chain contributed to the BACE1 inhibitory activities.

3.2. Antioxidant Activities

The *in vitro* antioxidant activities of these compounds were assessed by DPPH and ABTS^{•+} assays. DPPH and ABTS^{•+} (both stable radicals) are widely used to evaluate the antioxidant capacity of complex mixtures and individual compounds [20]. The *in vitro* antioxidant activity of the target compounds in comparison with Trolox was evaluated by DPPH and ABTS^{•+} assays. The IC₅₀ value is defined as the concentration of sample that causes 50% loss of the radical. The data obtained was summarized in Table 1. The IC₅₀s for Trolox in DPPH and ABTS^{•+} assays were 21.53 μM and 26.83 μM. Only one phenolic hydroxyl group substituted compounds showed good antioxidant activity in ABTS^{•+} assay, for example, the IC₅₀s for **D1**, **D4**, **D6**, **D7**, **D8**, **D11**, **D13** and **D18** were 27.14 μM, 27.79 μM, 45.82 μM, 40.11 μM, 83.45 μM,

BACE1 inhibitors with antioxidant activity

72.91 μM , 40.63 μM and 27.56 μM respectively. When the two phenolic hydroxyl groups were introduced into the benzene ring, the antioxidant activities were enhanced. For example, the IC_{50} s for **D3** in DPPH and $\text{ABTS}^{+\cdot}$ assays were 18.67 μM and 24.83 μM , the IC_{50} s for **D5** in DPPH and $\text{ABTS}^{+\cdot}$ assays were 53.64 μM and 23.76 μM , and the IC_{50} s for **D12** in DPPH and $\text{ABTS}^{+\cdot}$ assays were 35.21 μM and 35.58 μM . This information confirmed that the phenolic hydroxyl group was very important for antioxidant activities.

3.3. Molecular Docking Studies

Considering that compound **D1** exhibited the most potent BACE1 inhibitory activity with its IC_{50} was 1.80 μM , and good antioxidant activities with its IC_{50} s in DPPH and $\text{ABTS}^{+\cdot}$ assays were 67.85 μM and 27.14 μM , so **D1** was selected for molecular docking studies. As shown in Fig. 2, compound **D1** could extend deep into the cavity of BACE1, and combine excellently with hydrophilic surface and hydrophobic surface (Fig. 2), thus contributing to the ligand affinity. As expected, the amino group in the aminopyridine moiety made two hydrogen bonds with Asp32 and Asp228, and the nitrogen atom in the aminopyridine moiety made one hydrogen bond with Asp32. Furthermore, the amide bond in the side chain also formed two hydrogen bonds with the active sites, the carbonyl group formed one hydrogen bond with Gln73 and the amino group formed one hydrogen with Thr231. These actions might verify that **D1** had potent inhibitory activity against BACE1.




Fig. (2). Molecular docking studies of compound **D1** with BACE 1 protein.

4. CONCLUSION

In summary, we have synthesized new class of BACE1 inhibitors with antioxidant activities by molecular hybridization of the 2-amino-pyridine with some antioxidant natural products. The amino-pyridine could form hydrogen bonds with with Asp32 and Asp228, and the amide bond in the side chain also formed two hydrogen bonds with Gln73 and Thr231. Furthermore, the phenolic hydroxyl group in the side chain contributed to the antioxidant activities. These information was very important for BACE1 inhibitory activities.

5. EXPERIMENTAL

5.1. Chemistry: General Procedures

Reagents and solvents were used without further purification unless otherwise

BACE1 inhibitors with antioxidant activity

specified. Air- and moisture-sensitive liquids and solutions were transferred *via* syringe or stainless steel cannula. Organic solutions were concentrated below 45°C at approximately 20 mm Hg by rotary evaporation. All nonaqueous reactions were carried out under anhydrous conditions using flame-dried glassware within a nitrogen atmosphere in dry, freshly distilled solvents, unless otherwise stated. Yields referred to chromatographical separation, unless otherwise noted. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.15~0.20 mm Yantai silica gel plates (RSGF 254) (Yantai Chemical Industry Research Institute, Yantai, Shandong Province, China) using ultraviolet (UV) light as the visualizing agent. Chromatography was performed on Qingdao silica gel (160~200 mesh) (Qingdao Banke separation materials Company Limited, Qingdao, Shandong Province, China) using petroleum ether (60~90) and ethyl acetate as the eluanting solvent. Melting points (mp) were measured on a WRS-1B apparatus and were uncorrected. ¹H NMR spectra were obtained using a Bruker AV-400 (400 MHz) (Bruker Corporation, Germany). Chemical shifts were recorded in parts per million (ppm) downfield from tetramethylsilane. J-values were given in Hertz (Hz). Abbreviations used were singlet (s), doublet (d), triplet (t), quartet (q), broad (b), and multiplet (m). Electrospray ionisation tandem mass spectrometry (ESI-MS) was recorded on a Waters Synapt high definition mass spectrometry (HDMS) spectrometer.

2-(6-Methylpyridin-2-yl)isoindoline-1,3-dione (S2)

6-Methylpyridin-2-amine (S1) (5.00 g, 46.30 mmol) and phthalic anhydride (6.85 g, 46.30 mmol, 1.0 equiv.) were added into glacial acetic acid (20 ml), then the solution was refluxed for 5 h under the nitrogen. After the reaction was complete by TLC analysis, it was poured into cold water (200 ml), the solid appeared was filtered, washed with water and then dried under vacuum to afford S2 as white solid (10.49 g, 95.2% yield). mp 193-194°C. ¹H NMR (400 MHz, CDCl₃) δ 2.65 (s, 3H), 7.26 (dd, $J_1 = 7.8$ Hz, $J_2 = 10.8$ Hz, 2H), 7.77-7.83 (m, 3H), 7.99 (dd, $J_1 = 3.0$ Hz, $J_2 = 5.5$ Hz, 2H). ESI-MS: m/z 239 [M+H]⁺, 261 [M+Na]⁺.

2-(6-(Bromomethyl)pyridin-2-yl)isoindoline-1,3-dione (S3)

S2 (5.00 g, 21.01 mmol) was added into a solution of azodiisobutyronitrile (344.56 mg, 2.101 mmol, 0.1 equiv.) in DMF (90 ml), N-bromosuccinimide (4.114 g, 23.11 mmol, 1.1 equiv.) was then added into this solution in three parts every 30 minutes, after this mixture was refluxed for 5 h, it was concentrated and then purified by column chromatography using 10% ethyl acetate in petroleum ether as eluent to afford S3 (3.10 g, 46.7%) as white solid. mp 177-179°C. ¹H NMR (400 MHz, CDCl₃) δ 4.62 (s, 2H), 7.38 (d, $J = 7.8$ Hz, 1H), 7.57 (d, $J = 7.3$ Hz, 1H), 7.84 (dd, $J_1 = 3.1$ Hz, $J_2 = 5.5$ Hz, 2H), 7.93 (t, 1H), 8.00 (dd, $J_1 = 3.1$ Hz, $J_2 = 5.5$ Hz, 2H). ESI-MS: m/z 317 [M+H]⁺, 239 [M+Na]⁺.

2-(2-(1,3-dioxoisindolin-2-yl)methyl)isoindoline-1,3-dione (S5)

Phthalimide potassium salt (2.93 g, 15.82 mmol, 1.0 equiv.) was added into a solution of S3 (5.00 g, 15.82 mmol) in DMF (50 ml), after this mixture was refluxed for 4 h, it was poured into cold water (500 ml), the solid appeared was filtered, dried and then purified by column chromatography using 2% methanol in dichloromethane as eluent to afford S5 (5.47 g, 90.3%) as yellow solid. mp 114-116°C. ¹H NMR (400

BACE1 inhibitors with antioxidant activity

MHz, CDCl₃) δ 4.85 (s, 2H), 6.38 (d, $J = 8.0$ Hz, 1H), 6.59 (d, $J = 8.0$ Hz, 1H), 7.35-7.39 (m, 1H), 7.71-7.82 (m, 4H), 7.88-7.97 (m, 4H). ESI-MS: m/z 384 [M+H]⁺, 406 [M+Na]⁺.

6-(Aminomethyl)pyridin-2-amine (S6)

S5 (5.00 g, 13.05 mmol) was added into 40 ml concentrated hydrochloric acid, after the mixture was refluxed for 20 h, it was filtered and washed with water, then the crude product was recrystallized from ethanol to afford S6 (1.50 g, 93.7%) as yellow solid. mp 201-203°C. ¹H NMR (400 MHz, D₂O) δ 4.25 (s, 2H), 6.89 (d, $J = 8.0$ Hz, 1H), 6.98 (d, $J = 9.0$ Hz, 1H), 7.85 (t, 1H). ESI-MS: m/z 124 [M+H]⁺, 146 [M+Na]⁺.

Synthesis of D1–D18

The natural acid (0.52 mmol) was added into a solution of HOBT (84 mg, 0.62 mmol, 1.2 equiv.), EDCI (119 mg, 0.62 mmol, 1.2 equiv.), DIPEA (343 μ L, 2.08 mmol, 4.0 equiv.) in 10 ml DMF at 0 °C, 15 min later, S6 (76 mg, 0.62 mmol, 1.2 equiv.) was added into this solution. After the mixture was reacted at 25 °C for 12 h, it was poured into 100 ml cold water, and then extracted with ethyl acetate (30 ml \times 4). The ethyl acetate layer was washed with saturated salt water, dried over anhydrous sodium sulfate, concentrated and purified by column chromatography using 10% ethyl acetate in petroleum ether as eluent to afford D1–D18 (yields 78.8%–89.6%).

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (D1)

Yield 81.2%, white solid. mp 95-99°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.81 (s, 3H), 4.23 (d, $J = 8.0$ Hz, 2H), 5.89 (s, 2H), 6.31 (d, $J = 8.0$ Hz, 1H), 6.40 (d, $J = 8.0$ Hz, 1H), 6.57 (d, $J = 16.6$ Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 1H), 7.01-7.03 (m, 1H), 7.14 (s, 1H), 7.32-7.38 (m, 2H), 8.36 (t, 1H). ESI-MS: m/z 300 [M+H]⁺, 322 [M+Na]⁺.

N-((6-Aminopyridin-2-yl)methyl)cinnamamide (D2)

Yield 78.8%, white solid. mp 140-142°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.25 (d, $J = 8.0$ Hz, 2H), 5.91 (s, 2H), 6.32 (d, $J = 8.0$ Hz, 1H), 6.41 (d, $J = 8.0$ Hz, 1H), 6.75 (d, $J = 16.0$ Hz, 1H), 7.31-7.35 (m, 1H), 7.38-7.49 (m, 4H), 7.57-7.59 (m, 2H), 8.54 (t, 1H). ESI-MS: m/z 254 [M+H]⁺, 276 [M+Na]⁺.

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(3,4-dihydroxyphenyl)acrylamide (D3)

Yield 83.5%, white solid. mp 195-197°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.23 (s, 2H), 5.89 (s, 2H), 6.31 (d, $J = 8.0$ Hz, 1H), 6.39-6.44 (m, 2H), 6.72 (d, $J = 8.0$ Hz, 1H), 6.82 (d, $J = 8.0$ Hz, 1H), 6.95 (s, 1H), 7.23-7.35 (m, 2H), 8.41 (s, 1H). ESI-MS: m/z 286 [M+H]⁺, 308 [M+Na]⁺.

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(3-hydroxy-4-methoxyphenyl)acrylamide (D4)

Yield 85.8%, white solid. mp 214-217°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.80 (s, 3H), 4.23 (s, 2H), 5.91 (s, 2H), 6.32 (d, $J = 8.0$ Hz, 1H), 6.41 (d, $J = 16.0$ Hz, 1H), 6.51 (d, $J = 16.0$ Hz, 1H), 6.93-7.00 (m, 3H), 7.30-7.36 (m, 2H), 8.43 (t, 1H), 9.19 (s, 1H). ESI-MS: m/z 300 [M+H]⁺, 322 [M+Na]⁺.

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(3,5-dihydroxy-4-methoxyphenyl)acrylamide (D5)

Yield 82.1%, white solid. mp 96-99°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.80 (s, 6H), 4.26 (s, 2H), 6.06 (s, 2H), 6.35 (d, $J = 8.0$ Hz, 1H), 6.42 (d, $J = 8.0$ Hz, 1H), 6.63

BACE1 inhibitors with antioxidant activity

(d, $J = 16.0$ Hz, 1H), 6.88 (s, 2H), 7.35-7.39 (m, 2H), 8.41 (t, 1H), 8.84 (s, 1H). ESI-MS: m/z 316 $[M+H]^+$, 338 $[M+Na]^+$.

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(4-hydroxyphenyl)acrylamide (D6)

Yield 89.6%, white solid. mp 70-72°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.24 (s, 2H), 5.90 (s, 2H), 6.31 (d, $J = 8.0$ Hz, 1H), 6.40 (d, $J = 8.0$ Hz, 1H), 6.53 (d, $J = 16.0$ Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.40 (d, $J = 12.2$ Hz, 2H), 8.42 (t, 1H), 9.97 (s, 1H). ESI-MS: m/z 270 $[M+H]^+$, 292 $[M+Na]^+$.

(E)-N-((6-Aminopyridin-2-yl)methyl)-3-(2-hydroxyphenyl)acrylamide (D7)

Yield 80.3%, white solid. mp 83-87°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.24 (d, $J = 8.0$ Hz, 2H), 5.91 (s, 2H), 6.31 (d, $J = 8.0$ Hz, 1H), 6.40 (d, $J = 8.0$ Hz, 1H), 6.74-6.91 (m, 3H), 7.19 (t, 1H), 7.33 (t, 1H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.67 (d, $J = 16.0$ Hz, 1H), 8.50 (t, 1H), 10.07 (s, 1H). ESI-MS: m/z 270 $[M+H]^+$, 292 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-4-hydroxybenzamide (D8)

Yield 88.1%, white solid. mp 200-203°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.30 (d, $J = 8.0$ Hz, 2H), 5.89 (s, 2H), 6.29 (d, $J = 8.0$ Hz, 1H), 6.38 (d, $J = 8.0$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 2H), 7.29-7.33 (m, 1H), 7.78 (d, $J = 8.0$ Hz, 2H), 8.67 (t, 1H), 9.99 (s, 1H). ESI-MS: m/z 244 $[M+H]^+$, 266 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)benzamide (D9)

Yield 82.7%, white solid. mp 142-144°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.34 (d, $J = 8.0$ Hz, 2H), 5.90 (s, 2H), 6.30 (d, $J = 8.0$ Hz, 1H), 6.41 (d, $J = 8.0$ Hz, 1H), 7.30-7.34 (m, 1H), 7.47-7.55 (m, 3H), 7.92 (d, $J = 8.0$ Hz, 2H), 8.95 (t, 1H). ESI-MS: m/z 228 $[M+H]^+$, 260 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-4-methoxybenzamide (D10)

Yield 80.9%, white solid. mp 178-180°C. ^1H NMR (400 MHz, DMSO- d_6) δ 3.82 (s, 3H), 4.32 (d, $J = 8.0$ Hz, 2H), 5.87 (s, 2H), 6.30 (d, $J = 8.0$ Hz, 1H), 6.39 (d, $J = 8.0$ Hz, 1H), 7.01 (d, $J = 8.0$ Hz, 2H), 7.31 (t, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 8.79 (t, 1H). ESI-MS: m/z 258 $[M+H]^+$, 280 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-2-hydroxybenzamide (D11)

Yield 79.5%, white solid. mp 169-171°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.37 (d, $J = 8.0$ Hz, 2H), 5.91 (s, 2H), 6.32 (d, $J = 8.0$ Hz, 1H), 6.43 (d, $J = 8.0$ Hz, 1H), 6.89-6.93 (m, 2H), 7.33 (t, 1H), 7.42 (t, 1H), 7.93 (d, $J = 8.0$ Hz, 1H), 9.27 (t, 1H). ESI-MS: m/z 244 $[M+H]^+$, 266 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-3,4-dihydroxybenzamide (D12)

Yield 83.9%, white solid. mp 116-119°C. ^1H NMR (400 MHz, DMSO- d_6) δ 4.27 (d, $J = 8.0$ Hz, 2H), 5.88 (s, 2H), 6.29 (d, $J = 8.0$ Hz, 1H), 6.36 (d, $J = 8.0$ Hz, 1H), 6.78 (d, $J = 8.0$ Hz, 1H), 7.25-7.33 (m, 3H), 8.60 (t, 1H). ESI-MS: m/z 260 $[M+H]^+$, 282 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-4-hydroxy-3-methoxybenzamide (D13)

Yield 85.3%, white solid. mp 87-90°C. ^1H NMR (400 MHz, DMSO- d_6) δ 3.79 (s, 3H), 4.30 (d, $J = 8.0$ Hz, 2H), 5.87 (s, 2H), 6.29 (d, $J = 8.0$ Hz, 1H), 6.38 (d, $J = 8.0$ Hz, 1H), 6.74 (d, $J = 8.0$ Hz, 1H), 7.30 (t, 1H), 7.38 (d, $J = 8.0$ Hz, 1H), 7.43 (s, 1H), 8.62 (t, 1H). ESI-MS: m/z 274 $[M+H]^+$, 296 $[M+Na]^+$.

N-((6-Aminopyridin-2-yl)methyl)-4-fluorobenzamide (D14)

BACE1 inhibitors with antioxidant activity

Yield 82.8%, white solid. mp 157-160°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.33 (d, *J* = 8.0 Hz, 2H), 5.93 (s, 2H), 6.31 (d, *J* = 8.0 Hz, 1H), 6.40 (d, *J* = 8.0 Hz, 1H), 7.32 (t, 3H), 7.99 (t, 2H), 9.00 (t, 1H). ESI-MS: *m/z* 246 [M+H]⁺, 268 [M+Na]⁺.

N-((6-Aminopyridin-2-yl)methyl)-3-bromobenzamide (D15)

Yield 84.4%, white solid. mp 162-164°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.31 (d, *J* = 8.0 Hz, 2H), 5.91 (s, 2H), 6.31 (d, *J* = 8.0 Hz, 1H), 6.41 (d, *J* = 8.0 Hz, 1H), 7.30-7.34 (m, 1H), 7.45-7.48 (m, 1H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.92 (d, *J* = 8.0 Hz, 1H), 8.10 (s, 1H), 9.10 (t, 1H). ESI-MS: *m/z* 306 [M+H]⁺, 328 [M+Na]⁺.

N-((6-Aminopyridin-2-yl)methyl)-2-chlorobenzamide (D16)

Yield 87.3%, white solid. mp 161-163°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.30 (d, *J* = 8.0 Hz, 2H), 5.92 (s, 2H), 6.32 (d, *J* = 8.0 Hz, 1H), 6.54 (d, *J* = 8.0 Hz, 1H), 7.35-7.50 (m, 4H), 7.90 (t, 1H), 8.89 (t, 1H). ESI-MS: *m/z* 262 [M+H]⁺, 284 [M+Na]⁺.

N-((6-Aminopyridin-2-yl)methyl)-2-hydroxy-2-phenylacetamide (D17)

Yield 84.2%, white solid. mp 78-80°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.14 (t, 2H), 4.99 (s, 1H), 5.88 (s, 2H), 6.29 (d, *J* = 8.0 Hz, 2H), 7.25-7.44 (m, 4H), 7.45 (d, *J* = 8.0 Hz, 2H), 8.37 (t, 1H). ESI-MS: *m/z* 258 [M+H]⁺, 280 [M+Na]⁺.

N-((6-Aminopyridin-2-yl)methyl)-2-(2-hydroxyphenyl)acetamide (D18)

Yield 80.6%, white solid. mp 167-170°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.48 (s, 2H), 4.12 (d, *J* = 8.0 Hz, 2H), 5.88 (s, 2H), 6.29 (d, *J* = 8.0 Hz, 1H), 6.39 (d, *J* = 8.0 Hz, 1H), 6.75 (t, 1H), 6.81 (d, *J* = 8.0 Hz, 1H), 7.11-7.28 (m, 2H), 7.31 (t, 1H), 8.37 (t, 1H), 9.72 (s, 1H). ESI-MS: *m/z* 258 [M+H]⁺, 280 [M+Na]⁺.

5.2. BACE1 Inhibitory Activity Assay

The enzyme inhibition assay was evaluated according to the manufacturer instructions [21] using BACE1 FRET assay kit, Red (P2985, Thermo fisher). EGCG was used as a positive control. The BACE1 enzyme (purified baculovirus-expressed enzyme) was diluted with the assay buffer (50 mM sodium acetate, pH 4.5) to make a 3X working solution (1 Unit/ml). The peptide substrate (Rh-EVNLDAEFK-Quencher) was also diluted with the same assay buffer to provide the 3X stock solution (750 nM). The inhibitor stock solutions in DMSO were diluted with assay buffer to provide 3X solution of test compounds at different concentrations. The 3X solution of BACE1 enzyme (10 μl) and each inhibitor sample (10 μl) were placed in the 96-well plate and gently mixed. The substrate 3X solution (10 μl) was then added to this mixture in each well to start the reaction at the final reaction volume of 30 μl (the final concentration of DMSO in each sample and control wells was less than 4%). The reaction mixtures were incubated at 25 °C for 90 min in the dark and then the reaction was stopped with 10 μl of 2.5 mM sodium acetate. Fluorescence was monitored at 545 nm (excitation wavelength) and 585 nm (emission wavelength). The percentage of enzyme inhibition for each concentration of test compound was calculated compared to maximum enzyme activity wells (containing substrate plus enzyme) and baseline wells (containing substrate). IC₅₀ values (concentration of the compound that induces 50% inhibition of enzymatic activity) were calculated with CurveExpert software version 1.34 for Windows.

BACE1 inhibitors with antioxidant activity

5.2. DPPH Radical-Scavenging Activity Assay

The DPPH radical-scavenging activity assay was measured according to the method [22] with a few modifications. The sample (4~250 $\mu\text{mol/L}$, 100 μL) which was dissolved in ethanol was added to ethanol solution (100 μL) containing DPPH radicals (80 $\mu\text{mol/L}$) in 96 well plates. The mixture was shaken and left at room temperature for 30 min in the dark, and the absorption was measured at 517 nm, the Trolox was used as the positive control. A lower absorbance represents a higher DPPH scavenging activity. The percentage scavenging effect was calculated as scavenging rate (%) = $[1 - (A_1 - A_2)/A_0] \times 100\%$, where A_0 was the absorbance of the control (without sample), A_1 was the absorbance in the presence of the sample and A_2 was the absorbance without DPPH.

5.3. ABTS^{•+} Radical-Scavenging Activity Assay

The ABTS^{•+} radical-scavenging activity assay was measured according to a literature procedure [20]. $\text{K}_2\text{S}_2\text{O}_8$ (2 mmol/L) and ABTS (7 mmol/L) were dissolved and mixed in deionized water, reacting at room temperature for 12~16 h. The mixture (ABTS^{•+} stock solution) was then diluted by phosphate buffer solution to give an absorbance at 734 nm near 0.7, defined as the reference absorbance (A_0). A_0 decreased to a stable value (A_1) when ABTS^{•+} (100 μL) was mixed with the sample (1~62.5 $\mu\text{mol/L}$, 100 μL) for 6 min. The percentage scavenging effect was calculated as scavenging rate (%) = $[1 - (A_1 - A_2)/A_0] \times 100\%$, where A_0 was the absorbance of the control (without sample), A_1 was the absorbance in the presence of the sample and A_2 was the absorbance without ABTS^{•+}.

5.4. Docking Studies

Compound **D1** were docked into the crystal structures of BACE 1 (PDB ID: 3MSL) by using Discovery Studio 2.5. Standard precession with SD was used to dock **D1**. Optimization was performed on the following conditions: CHARMM for force field setting, an active site radius was 10.0 Å. Physicochemical properties and their scoring functions (a combination of interaction energy, hydrogen bonding, and electrostatic interactions) were used to select the final pose.

Acknowledgments

This work was financially supported by Natural Science Foundation of Jiangsu Province (BK20151563), Six Talents Project Funded by Jiangsu Province (2013-YY-010), Program for Excellent Talents in School of Pharmacy of Nanjing University of Chinese Medicine (15ZYXET-1), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions and Project Funded by the Flagship Major Development of Jiangsu Higher Education Institutions (PPZY2015A070), Key Laboratory of Therapeutic Material of Chinese Medicine, Jiangsu Province, State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine.

BACE1 inhibitors with antioxidant activity

References and notes

- [1] Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. *Physiol. Rev.*, **2001**, *81*, 741–766.
- [2] Lee, V.M.; Balin, B.J.; Otvos, L.Jr.; Trojanowski, J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. *Science*, **1991**, *251*, 675–678.
- [3] Vassar, R.; Kovacs, D.M.; Yan, R.; Wong, P.C. The beta-secretase enzyme BACE in health and Alzheimer's Disease: Regulation, cell Biology, function, and therapeutic potential. *J. Neurosci.*, **2009**, *29*, 12787–12794.
- [4] Sisodia, S.S.; St George-Hyslop, P.H. γ -Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? *Nat. Rev. Neurosci.*, **2002**, *3*, 281–290.
- [5] Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B.D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; Martin, L.; Louis, J.-C.; Yan, Q.; Richards, W.G.; Citron, M.; Vassar, R. Mice deficient in BACE1, the Alzheimer's β -secretase, have normal phenotype and abolished β -amyloid generation. *Nat. Neurosci.*, **2001**, *4*, 231–232.
- [6] Evin, G.; Lessene, G.; Wilkins, S. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. *Recent Pat. CNS Drug Discov.*, **2011**, *6*, 91–106.
- [7] Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A.K.; Zhang, X.C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. *Science*, **2000**, *290*, 150–153.
- [8] Ghosh, A.K.; Brindisi, M.; Tang, J. Developing β -secretase inhibitors for treatment of Alzheimer's disease. *J. Neurochem.*, **2012**, *120*, 71–83.
- [9] Hom, R.K.; Fang, L.Y.; Mamo, S.; Tung, J.S.; Guinn, A.C.; Walker, D.E.; Davis, D.L.; Gailunas, A.F.; Thorsett, E.D.; Sinha, S.; Knops, J.E.; Jewett, N.E.; Anderson, J.P.; John, V. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. *J. Med. Chem.*, **2003**, *46*, 1799–1802.
- [10] Albert, J.S. Progress in the development of beta-secretase inhibitors for Alzheimer's disease. *Prog. Med. Chem.*, **2009**, *48*, 133–161.
- [11] Hung, S.-Y.; Fu, W.-M. Drug candidates in clinical trials for Alzheimer's disease. *J. Biomed. Sci.*, **2017**, *24*, 47.
- [12] Ansari, M.A.; Scheff, S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. *J. Neuropathol. Exp. Neurol.*, **2010**, *69*, 155–167.
- [13] Nunomura, A.; Castellani, R.J.; Zhu, X.; Moreira, P.I.; Perry, G.; Smith, M.A. Involvement of oxidative stress in Alzheimer disease. *J. Neuropathol. Exp. Neurol.*, **2006**, *65*, 631–641.
- [14] Malamas, M.S.; Barnes, K.; Hui, Y.; Johnson, M.; Lovering, F.; Condon, J.; Fobare, W.; Solvibile, W.; Turner, J.; Hu, Y.; Manas, E.S.; Fan, K.; Olland, A.; Chopra, R.; Bard, J.; Pangalos, M.N.; Reinhart, P.; Robichaud, A.J. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors. *Bioorg. Med. Chem. Lett.*, **2010**, *20*, 2068–2073.
- [15] Cole, D.C.; Manas, E.S.; Stock, J.R.; Condon, J.S.; Jennings, L.D.; Aulabaugh, A.; Chopra, R.; Cowling, R.; Ellingboe, J.W.; Fan, K.Y.; Harrison, B.L.; Hu, Y.; Jacobsen, S.; Jin, G.; Lin, L.; Lovering, F.E.; Malamas, M.S.; Stahl, M.L.; Strand, J.; Sukhdeo, M.N.; Svenson, K.; Turner, M.J.; Wagner, E.; Wu, J.; Zhou, P.; Bard, J. *J. Med. Chem.*, **2006**, *49*, 6158–6161.
- [16] Gay, N.H.; Phopin, K.; Suwanjang, W.; Songtawee, N.; Ruankham, W.; Wongchitrat, P.; Prachayasittikul, S.; Prachayasittikul, V. Neuroprotective effects of phenolic and carboxylic

BACE1 inhibitors with antioxidant activity

- acids on oxidative stress-induced toxicity in human neuroblastoma SH-SY5Y cells. *Neurochem. Res.*, **2018**, *43*, 619–636.
- [17] Tańska, M.; Mikołajczak, N.; Konopka, I. Comparison of the effect of sinapic and ferulic acids derivatives (4-vinylsyringol vs. 4-vinylguaiacol) as antioxidants of rapeseed, flaxseed, and extra virgin olive oils. *Food Chem.*, **2018**, *240*, 679–685.
- [18] Liu, J.; Pu, H.; Chen, C.; Liu, Y.; Bai, R.; Kan, J.; Jin, C. Reaction mechanisms and structural and physicochemical properties of caffeic acid grafted chitosan synthesized in ascorbic acid and hydroxyl peroxide redox system. *J. Agric. Food Chem.*, **2018**, *66*, 279–289.
- [19] Jeon, S.Y.; Bae, K.; Seong, Y.H.; Song, K.S. Green tea catechins as a BACE1 (beta-secretase) inhibitor. *Bioorg Med Chem Lett.*, **2003**, *13*, 3905–3908.
- [20] Liu, Z.Q. Chemical methods to evaluate antioxidant ability. *Chem. Rev.* **2010**, *110*, 5675–5691.
- [21] Al-Tel, T.H.; Semreen, M.H.; Al-Qawasmeh, R.A.; Schmidt, M.F.; El-Awadi, R.; Ardah, M.; Zaarour, R.; Rao, S.N.; El-Agnaf, O. Design, synthesis, and qualitative structure–activity evaluations of novel β -secretase inhibitors as potential Alzheimer’s drug leads. *J. Med. Chem.*, **2011**, *54*, 8373–8385.
- [22] Wang, H.; Gao, D.X.; Zhou, G.C.; Cai, L.; Yao, W.B. *In vitro* and *in vivo* antioxidant activity of aqueous extract from *Choerospondias axillaris* fruit. *Food Chem.* **2008**, *106*, 888–895.